Electrolyte-Free Parenteral Nutrition Emulsion.

The point of an electrolyte-free formulation is that the prescriber sets each electrolyte independently rather than accepting a fixed premix. Sodium is the dominant extracellular cation and the main determinant of infused fluid distribution. Additions of this kind are made by a clinician against measured serum values.

Potassium is the principal intracellular cation and its infused amount has to track measured serum concentration and renal handling. Separating it from the lipid base is what allows that individualisation. Compounding and monitoring of this sit entirely with the clinical team.

Magnesium is a required cofactor for hundreds of enzymes including every ATP-dependent step, so a nutrition regimen has to supply it. Divalent cations also affect emulsion droplet stability, which is one reason they are added separately and in a controlled order. Compatibility limits are set by the compounding pharmacy.

Calcium and inorganic phosphate form insoluble calcium phosphate above a solubility product that depends on pH, temperature, amino acid content and the order of addition. In a lipid emulsion any precipitate is hidden by the opacity, which is why compatibility charts and addition sequence exist. This is established compounding chemistry rather than a supplement pairing.

Inorganic phosphate is the reactive partner in calcium phosphate precipitation, so organic phosphate salts such as glycerophosphate are used where higher amounts are needed. Phosphate demand also rises sharply when carbohydrate is reintroduced after a period of low intake. Both points are standard clinical nutrition practice.

Zinc is the catalytic or structural metal in a large number of enzymes and transcription factors and is lost in significant amounts through gastrointestinal output. A lipid emulsion contributes essentially none. Trace element additions are dosed and monitored clinically.

Copper is required by cytochrome c oxidase, lysyl oxidase and superoxide dismutase, and it is excreted mainly in bile. Both facts shape how much is added and when it is reduced. This is established clinical pharmacology.

Selenium is the catalytic centre of the glutathione peroxidases that reduce lipid hydroperoxides. An infused emulsion delivers polyunsaturated fatty acids that those enzymes act on. The cofactor relationship is settled biochemistry.

Manganese is a cofactor for mitochondrial superoxide dismutase and several other enzymes, and it is cleared through bile. Because infusion bypasses the intestinal regulation of uptake, long-term regimens monitor it rather than assuming more is better. Dosing decisions belong to the clinical team.

Chromium is included in trace element additions on the basis of long-standing clinical convention and its role in normal glucose handling. Contamination of other components can contribute an unintended amount. The evidence base for the required amount is weaker than for zinc or copper.

Emulsions made from vegetable oils carry variable natural tocopherol, and the amount depends on the oil blend. Olive-rich and fish-oil-containing blends are formulated with tocopherol addition because of their differing oxidation susceptibility. Light exposure during infusion increases peroxide formation, which is why light-protective sets are used.

Phylloquinone travels with the plant oil fraction, so a soybean-oil emulsion delivers a meaningful amount while olive or fish oil blends deliver less. This matters for anyone whose vitamin K intake is being kept steady for a clinical reason. It is a property of the oil, not an added ingredient.

Thiamine pyrophosphate is the cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and transketolase, all of which run faster as carbohydrate load increases. Nutrition support in someone with low intake therefore includes thiamine from the outset. This is settled biochemistry and standard clinical practice.

Long-chain fatty acids need the carnitine palmitoyltransferase shuttle to reach the mitochondrial matrix for oxidation. Standard emulsions supply no carnitine, and endogenous synthesis may be limited in some clinical situations, particularly in preterm infants. Whether to add it is a prescriber decision.

Phosphatidylcholine synthesis is required for hepatic very low density lipoprotein assembly, which is how the liver exports triglyceride. Standard parenteral formulations supply little free choline, though the egg phospholipid emulsifier contributes some. This has been raised as a gap in long-term regimens.

Multi-chamber emulsions combine soybean, medium-chain, olive and fish oils in fixed ratios to give a particular fatty acid profile. The fish oil fraction supplies EPA and DHA, which shift the eicosanoid substrate balance. Which blend is used is a clinical choice made per patient.

Medium-chain fatty acids are oxidised more rapidly and do not require the carnitine shuttle for mitochondrial entry. Blending them with long-chain oils changes the oxidation profile of the infused lipid. Formulations differ in the ratio they use and none is presented here as preferable.